SCHEMBL4667428

SCHEMBL4667428

CN1CCC(CCOc2ccc(-c3cc(Nc4ccc(CON(OC=O)S(=O)(=O)c5ccccc5)cc4)ncn3)cc2F)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 7/20 0.35
BCR P11274 7/20 0.35
EGFR P00533 6/20 0.35
SYK P43405 1/20 0.34
FAAH O00519 3/20 0.33
IKBKE Q14164 1/20 0.33
TBK1 Q9UHD2 1/20 0.33
ERBB2 P04626 1/20 0.33
BACE1 P56817 1/20 0.33
FGFR1 P11362 2/20 0.33
FLT1 P17948 2/20 0.33
FLT4 P35916 2/20 0.33
KDR P35968 2/20 0.33
USP2 O75604 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
TSHR P16473 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL4667427 0.85 SYK (0.36) ABL1BCREGFRSYKFAAH
SCHEMBL4664347 0.83 USP2 (0.40) ABL1BCREGFRSYKIKBKE
SCHEMBL4667466 0.83 ABL1 (0.36) ABL1BCREGFRSYKFAAH
SCHEMBL4665785 0.82 EGFR (0.35) ABL1BCREGFRSYKIKBKE
SCHEMBL4665886 0.81 EGFR (0.37) ABL1BCREGFRSYKIKBKE
SCHEMBL4665896 0.80 MEN1 (0.38) ABL1BCREGFRSYKIKBKE
SCHEMBL4664360 0.80 SYK (0.35) ABL1BCREGFRSYKIKBKE
Formic Acid SCHEMBL4667464 0.78 AXL (0.40) ABL1BCREGFRFAAHIKBKE
Formic Acid SCHEMBL4665782 0.77 IKBKE (0.39) ABL1BCREGFRSYKIKBKE
Formic Acid SCHEMBL4664342 0.77 ABL1 (0.40) ABL1BCREGFRSYKIKBKE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 ABL1 24/4885BCR 402/4885EGFR 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.